CytomX Therapeutics Ownership | Who Owns CytomX Therapeutics?
CytomX Therapeutics Ownership Summary
CytomX Therapeutics is owned by 13.07% institutional investors, 0.77% insiders, and 86.16% retail investors. Vr adviser is the largest institutional shareholder, holding 12.06% of CTMX shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.07% of its assets in CytomX Therapeutics shares.
CTMX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | CytomX Therapeutics | 13.07% | 0.77% | 86.16% |
| Sector | Healthcare Stocks | 42.54% | 10.83% | 46.63% |
| Industry | Biotech Stocks | 45.22% | 10.75% | 44.04% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vr adviser | 15.56M | 12.06% | $49.64M |
| Fmr | 15.40M | 11.93% | $49.11M |
| Tang capital management | 11.07M | 8.57% | $35.30M |
| Perceptive advisors | 9.68M | 7.50% | $30.88M |
| Vanguard group | 8.95M | 6.93% | $28.54M |
| Orbimed advisors | 8.46M | 6.56% | $26.99M |
| Commodore capital lp | 7.69M | 5.96% | $24.54M |
| Millennium management | 3.22M | 3.79% | $3.32M |
| Baker bros. advisors lp | 4.25M | 3.29% | $13.56M |
| Balyasny asset management | 2.87M | 3.29% | $6.50M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Vr adviser | 15.56M | 2.79% | $49.64M |
| Exome asset management | 745.30K | 1.44% | $2.38M |
| Tang capital management | 11.07M | 1.36% | $35.30M |
| Adar1 capital management | 4.05M | 1.21% | $12.90M |
| Commodore capital lp | 7.69M | 1.20% | $24.54M |
| Ikarian capital | 3.37M | 1.09% | $10.76M |
| Perceptive advisors | 9.68M | 0.89% | $30.88M |
| Kynam capital management, lp | 3.65M | 0.87% | $11.63M |
| Vivo capital | 2.88M | 0.74% | $9.20M |
| Orbimed advisors | 8.46M | 0.64% | $26.99M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 15.40M | 0.00% | 6.16M |
| Ikarian capital | 3.37M | 1.09% | 3.37M |
| Balyasny asset management | 2.87M | 0.01% | 2.87M |
| Perceptive advisors | 9.68M | 0.89% | 2.69M |
| Vr adviser | 15.56M | 2.79% | 1.59M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Franklin resources | - | - | -5.77M |
| Bvf inc/il | - | - | -5.23M |
| Janus henderson group | - | - | -4.81M |
| Point72 asset management | 4.07M | 0.02% | -4.02M |
| Fairmount funds management | - | - | -3.90M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Ikarian capital | 3.37M | 1.09% | 3.37M | $10.76M |
| Balyasny asset management | 2.87M | 0.01% | 2.87M | $6.50M |
| Boothbay fund management | 1.24M | 0.06% | 1.24M | $3.95M |
| Exome asset management | 745.30K | 1.44% | 745.30K | $2.38M |
| Inspire investing | 522.48K | 0.16% | 522.48K | $1.67M |
Sold Out
| Holder | Change |
|---|---|
| Innealta capital | -2.00 |
| Raleigh capital management | -250.00 |
| Old point trust & financial services n a | -250.00 |
| Bell investment advisors | -388.00 |
| Federated hermes | -398.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | 36 | -59.09% | 16,872,803 | -87.34% | 13 | 0.12% | 20 | -64.91% | 7 | -58.82% |
| Jun 30, 2025 | 88 | 35.38% | 133,304,249 | 195.10% | 153 | 5.69% | 57 | 128.00% | 16 | -36.00% |
| Mar 31, 2025 | 66 | -7.04% | 45,273,213 | -3.09% | 51 | 1.72% | 26 | -25.71% | 25 | 19.05% |
| Dec 31, 2024 | 70 | -2.78% | 46,332,988 | -9.49% | 54 | 1.50% | 34 | 21.43% | 21 | -12.50% |
| Sep 30, 2024 | 70 | -9.09% | 50,859,222 | 0.34% | 59 | 1.57% | 27 | -35.71% | 23 | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard US Total Market Shares ETF | 2.46M | 3.07% | - |
| Vanguard Total Stock Mkt Idx Inv | 4.95M | 3.00% | -109.73K |
| Fidelity Advisor Biotechnology I | 3.44M | 2.09% | - |
| Franklin Biotechnology Discv A(acc)USD | 2.92M | 1.77% | -800.28K |
| Fidelity Stock Selector Small Cap | 2.72M | 1.65% | - |
| Fidelity Series Small Cap Opps | 2.39M | 1.45% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.71M | 1.04% | -749.87K |
| Vanguard Explorer Inv | 820.46K | 1.02% | - |
| Franklin Biotechnology Discovery A | 1.57M | 0.95% | -470.89K |
| Vanguard Strategic Small-Cap Equity Inv | 555.12K | 0.69% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Nov 06, 2025 | McCarthy Sean A. | CEO | Sell | $461.91K |
| Jun 16, 2025 | Ogden Christopher | Chief Financial Officer | Sell | $28.54K |
| Jun 13, 2025 | Ogden Christopher | Chief Financial Officer | Sell | $4.84K |
| Jun 16, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | $37.33K |
| Jun 16, 2025 | McCarthy Sean A. | CEO | Sell | $149.26K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | - | 4 |
| 2025 Q1 | - | 5 |
| 2024 Q3 | - | 5 |
| 2024 Q2 | - | - |
| 2024 Q1 | - | 5 |
CTMX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools